



Robert Greene Sterne  
Jorge A. Goldstein  
David K.S. Cornwell  
Robert W. Esmond  
Tracy-Gene G. Durkin  
Michele A. Cimbala  
Michael B. Ray  
Robert E. Sokohl  
Eric K. Steffe  
Michael Q. Lee  
Steven R. Ludwig  
John M. Covert  
Linda E. Horner  
Robert C. Millonig  
Donald J. Featherstone  
Timothy J. Shea, Jr  
Michael V. Messinger  
Judith U. Kim

Patrick E. Garrett  
Jeffrey T. Helvey  
Eldora L. Ellison  
Thomas C. Fiala  
Donald R. Banowitz  
Peter A. Jackman  
Jeffrey S. Weaver  
Brian J. Del Buono  
Edward W. Yee  
Vincent L. Capuano  
Virgil Lee Beaton  
Theodore A. Wood  
Elizabeth J. Haanes  
Joseph S. Ostroff  
Frank R. Cottingham  
Daniel A. Klein  
Jason D. Eisenberg  
Michael D. Specht

Tracy L. Muller  
Jon E. Wright  
LuAnne M. DeSantis  
Ann E. Summerfield  
Helene C. Carlson  
Cynthia M. Bouchez  
Timothy A. Doyle  
Gaby L. Longworth  
Lori A. Gordon  
Laura A. Vogel  
Bryan S. Wade  
Bashir M.S. Ali  
Shannon A. Carroll  
Matthew E. Kelley  
Anbar F. Khal  
Michelle K. Holoubek  
Marsha A. Rose  
Young Tang

Christopher J. Walsh  
W. Blake Coblenz  
James J. Pohl\*  
John T. Haran  
Mark W. Rygiel  
Kevin W. McCabe  
  
Registered Patent Agents  
Karen R. Markowicz  
Matthew J. Dowd  
Katrina Yujian Pei Quach  
Bryan L. Skelton  
Robert A. Schwartzman  
Victoria S. Rutherford  
Simon J. Elliott  
Julie A. Heider  
Mita Mukherjee

Scott M. Woodhouse  
Liliana Di Nola-Baron  
Peter A. Socarras  
Jeffrey K. Mills  
Danielle L. Letting  
Lori Brandes  
Steven C. Oppenheimer

Of Counsel  
Edward J. Kessler  
Kenneth C. Bass III  
Marvin C. Guthrie

\* Admitted only in Maryland  
\* Admitted only in Virginia  
• Practice Limited to  
Federal Agencies

July 24, 2006

WRITER'S DIRECT NUMBER:  
(202) 772-8764

INTERNET ADDRESS:  
CWALSH@SKGF.COM

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

Art Unit 1624

Mail Stop Amendment

Re: U.S. Utility Patent Application  
Application No. 09/518,501; Filed: March 3, 2000  
For: **Novel Phosphorus-containing Prodrugs**  
Inventors: Erion *et al.*  
Our Ref: 2358.0010002/RWE/CJW

Sir:

Transmitted herewith for appropriate action are the following documents:

1. Supplemental Information Disclosure Statement;
2. Form PTO/SB/08A (1 sheet);
3. Form PTO/SB/08B (1 sheet);
4. Copies of thirteen (12) references (Documents B6, B7 and C128-C137); and
5. Return postcard.


It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

Commissioner for Patents  
July 24, 2006  
Page 2

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.


Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Christopher J. Walsh  
Attorney for Applicants  
Registration No. 55,709

CJW/dab  
561165\_1.DOC  
Enclosures



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Erion *et al.*

Appl. No.: 09/518,501

Filed: March 3, 2000

For: **Novel Phosphorus-containing  
Prodrugs**

Confirmation No.: 7608

Art Unit: 1624

Examiner: T. McKenzie

Atty. Docket: 2358.0010002/RWE/CJW

**Supplemental Information Disclosure Statement**

***Mail Stop Amendment***

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

Sir:

Listed on accompanying IDS Forms are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. The numbering on this Supplemental Information Disclosure Statement is a continuation of the numbering in Applicants' Supplemental Information Disclosure Statement filed on March 28, 2006, in connection with the above-captioned application. Copies of documents B6, B7 and C128-C137 are submitted. However, in accordance with 37 C.F.R. § 1.98(a)(2), no copies of U.S. patents and patent application publications cited on the attached IDS Forms are submitted.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached IDS Forms based

on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

This Information Disclosure Statement is being filed before the mailing of a first Office Action after the filing of a request for continued examination under 37 C.F.R. § 1.114. No statement or fee is required.

It is respectfully requested that the Examiner initial and return a copy of the enclosed IDS Forms, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Christopher J. Walsh  
Attorney for Applicants  
Registration No. 55,709

Date: July 24, 2006

1100 New York Avenue, N.W.  
Washington, D.C. 20005-3934  
(202) 371-2600

561153\_1.DOC

Substitute for form 1449/PTO

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

**Complete if Known**

Application Number	09/518,501
Filing Date	March 3, 2000
First Named Inventor	Mark D. Erion
Art Unit	1624
Examiner Name	T. McKenzie
Attorney Docket Number	2358.0010002/RWE/CJW (MTI-013)

[illegible][illegible]


561117 1.DOC

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \*Applicant's unique citation designation number (optional). \*See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. \*Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). \*For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. \*Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. \*Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

**If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.**



PTO/SB/08B (07-05)

Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use as many sheets as necessary)				Application Number	09/518,501
				Filing Date	March 3, 2000
				First Named Inventor	Mark D. Erion
				Art Unit	1624
				Examiner Name	T. McKenzie
Sheet	1	of	1	Attorney Docket Number	2358.0010002/RWE/CJW (MTI-013)

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	C128	ARNÉR, E.S.J. and ERIKSSON, S., "Mammalian Deoxyribonucleoside Kinases," <i>Pharmac. Ther.</i> 67(2): 155-186, Elsevier Science Ltd. (1995).	
	C129	ELLIOTT, R.L. <i>et al.</i> , "Synthesis and Biological Evaluation of Phosphoramidate Peptide Inhibitors of Enkephalinase and Angiotensin-Converting Enzyme," <i>J. Med. Chem.</i> 28: 1208-1216, American Chemical Society (1985).	
	C130	ERION, M.D. <i>et al.</i> , "HepDirect Prodrugs for Targeting Nucleotide-Based Antiviral Drugs to the Liver," <i>Current Opinion in Investigational Drugs</i> 7(2): 109-117, The Thomson Corporation (2006).	
	C131	FREEMAN, S. and ROSS, K., "Prodrug Design for Phosphates and Phosphonates," <i>Progress in Medicinal Chemistry</i> 34: 111-147, Elsevier Science B.V. (1997).	
	C132	GORENSTEIN, D.G. <i>et al.</i> , "Stereochemical Effects in the Reactions of Epimeric 2-Aryloxy-2-oxy-1,3,2-dioxaphosphorinanes and Oxazaphosphorinanes," <i>J. Am. Chem. Soc.</i> 102: 5077-5081, American Chemical Society (1980).	
	C133	HULST, R. <i>et al.</i> , "A New <sup>31</sup> P NMR Method for the Enantiomeric Excess Determination of Alcohols, Amines and Amino Acid Esters," <i>Tetrahedron Letters</i> 34(8): 1339-1342, Pergamon Press Ltd. (1993).	
	C134	LOREY, M. and MEIER, C., "A New Cyclic Phosphoramidate D4T Prodrug Approach CycloAmb-D4T-Phosphoramidates," <i>Nucleosides &amp; Nucleotides</i> 18(4&5): 947-948, Marcel Dekker, Inc. (1999).	
	C135	MERCKLING, F.A. and RÜEDI, P., "Diastereoselectivity in Nucleophilic Displacement Reactions at Phosphorus; Isolation and Characterization of a Pentacoordinated Intermediate," <i>Tetrahedron Letters</i> 37(13): 2217-2220, Elsevier Science Ltd. (1996).	
	C136	REDDY, K.R. <i>et al.</i> , "Stereoselective Synthesis of Nucleoside Monophosphate HepDirect <sup>TM</sup> Prodrugs," <i>Tetrahedron Letters</i> 46: 4321-4324, Elsevier Ltd. (2005).	
	C137	TEN HOEVE, W. and WYNBERG, H. "The Design of Resolving Agents. Chiral Cyclic Phosphoric Acids," <i>J. Org. Chem.</i> 50: 4508-4514, American Chemical Society (1985).	

561118\_1.DOC

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.